The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Alterations of pre‐mRNA splicing in cancer
Abstract
Recent genomewide analyses of alternative splicing (AS) indicate that up to 70% of human genes may have alternative splice forms, suggesting that AS together with various posttranslational modifications plays a major role in the production of proteome complexity. Splice‐site selection under normal physiological conditions is regulated in the developmental stage in a tissue type‐specific manner by changing the concentrations and the activity of splicing regulatory proteins. Whereas spliceosomal errors resulting in the production of aberrant transcripts rarely occur in normal cells, they seem to be an intrinsic property of cancer cells. Changes in splice‐site selection have been observed in various types of cancer and may affect genes implicated in tumor progression (for example, CD44, MDM2, and FHIT) and in susceptibility to cancer (for example, BRCA1 and APC). Splicing defects can arise from inherited or somatic mutations in cis‐acting regulatory elements (splice donor, acceptor and branch sites, and exonic and intronic splicing enhancers and silencers) or variations in the composition, concentration, localization, and activity of regulatory proteins. This may lead to altered efficiency of splice‐site recognition, resulting in overexpression or down‐regulation of certain splice variants, a switch in splice‐site usage, or failure to recognize splice sites correctly, resulting in cancer‐specific splice forms. At least in some cases, changes in splicing have been shown to play a functionally significant role in tumorigenesis, either by inactivating tumor suppressors or by gain of function of proteins promoting tumor development. Moreover, cancer‐specific splicing events may generate novel epitopes that can be recognized by the host's immune system as cancer specific and may serve as targets for immunotherapy. Thus, the identification of cancer‐specific splice forms provides a novel source for the discovery of diagnostic or prognostic biomarkers and tumor antigens suitable as targets for therapeutic intervention. © 2005 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Listening to silence and understanding nonsense: exonic mutations that affect splicing
Cartegni, L., Chew, S. L., & Krainer, A. R. (2002) · Nature Reviews Genetics · doi:10.1038/nrg775 · Cited by 2,209
Alternative splicing in disease and therapy
Garcia-Blanco, M. A., Baraniak, A. P., & Lasda, E. L. (2004) · Nature Biotechnology · doi:10.1038/nbt964 · Cited by 527
Signal-dependent regulation of splicing via phosphorylation of Sam68
Matter, N., Herrlich, P., & König, H. (2002) · Nature · doi:10.1038/nature01153 · Cited by 458
An Alternative Splice Form of Mdm2 Induces p53-independent Cell Growth and Tumorigenesis
Steinman, H. A., Burstein, E., Lengner, C., Gosselin, J., Pihan, G., Duckett, C. S., & Jones, S. N. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m305966200 · Cited by 96
Cited by
CD44: can a cancer-initiating cell profit from an abundantly expressed molecule?
Zöller, M. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3023 · Cited by 1,112
Mechanism of alternative splicing and its regulation
WANG, Y., LIU, J., HUANG, B., XU, Y.-M., LI, J., HUANG, L.-F., LIN, J., ZHANG, J., MIN, Q.-H., YANG, W.-M., et al. (2015) · Biomedical Reports · doi:10.3892/br.2014.407 · Cited by 475
Krawczak, M., Thomas, N. S. T., Hundrieser, B., Mort, M., Wittig, M., Hampe, J., & Cooper, D. N. (2007) · Human Mutation · doi:10.1002/humu.20400 · Cited by 374
Intron retention is a widespread mechanism of tumor-suppressor inactivation
Jung, H., Lee, D., Lee, J., Park, D., Kim, Y. J., Park, W.-Y., Hong, D., Park, P. J., & Lee, E. (2015) · Nature Genetics · doi:10.1038/ng.3414 · Cited by 339
Nowak, D. G., Woolard, J., Amin, E. M., Konopatskaya, O., Saleem, M. A., Churchill, A. J., Ladomery, M. R., Harper, S. J., & Bates, D. O. (2008) · Journal of Cell Science · doi:10.1242/jcs.016410 · Cited by 339
Metadata
- Authors
- Kalnin̨a, Z., Zayakin, P., Silin̨a, K., & Linē, A.
- Venue
- Genes, Chromosomes and Cancer
- Publisher
- Wiley
- Published
- 2005-01-11
- Volume
- 42
- Issue
- 4
- Pages
- 342-357
- ISSN
- 1045-2257 (ISSN-L)
- 1098-2264
- OpenAlex
- W2004297363
- Cited by
- 196
- References
- 4
- FWCI
- 9.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.